Eidos Therapeutics Inc (NASDAQ:EIDX) – Analysts at Svb Leerink cut their FY2019 earnings per share estimates for Eidos Therapeutics in a research note issued on Thursday, December 5th. Svb Leerink analyst M. Foroohar now expects that the company will post earnings per share of ($1.03) for the year, down from their prior estimate of ($1.02). Svb Leerink also issued estimates for Eidos Therapeutics’ Q4 2019 earnings at ($0.51) EPS, Q1 2020 earnings at ($0.60) EPS, Q2 2020 earnings at ($0.62) EPS, Q3 2020 earnings at ($0.77) EPS, Q4 2020 earnings at ($0.81) EPS and FY2020 earnings at ($2.79) EPS.
Several other research analysts also recently issued reports on EIDX. Piper Jaffray Companies upped their price objective on Eidos Therapeutics from $55.00 to $75.00 and gave the stock an “overweight” rating in a report on Tuesday, November 19th. Zacks Investment Research raised Eidos Therapeutics from a “hold” rating to a “buy” rating and set a $52.00 price objective on the stock in a report on Monday, November 18th. Roth Capital increased their price target on Eidos Therapeutics from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, November 1st. ValuEngine downgraded Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, Barclays downgraded Eidos Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $37.00 to $45.00 in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $52.00.
Eidos Therapeutics (NASDAQ:EIDX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.48. The firm had revenue of $26.69 million for the quarter.
Several hedge funds have recently bought and sold shares of EIDX. Bank of Montreal Can lifted its stake in shares of Eidos Therapeutics by 151.8% in the 2nd quarter. Bank of Montreal Can now owns 1,385 shares of the company’s stock valued at $43,000 after purchasing an additional 835 shares during the period. SG Americas Securities LLC bought a new stake in shares of Eidos Therapeutics in the 2nd quarter valued at $125,000. Metropolitan Life Insurance Co NY bought a new stake in shares of Eidos Therapeutics in the 1st quarter valued at $143,000. Strs Ohio increased its position in shares of Eidos Therapeutics by 457.1% in the 2nd quarter. Strs Ohio now owns 11,700 shares of the company’s stock valued at $363,000 after buying an additional 9,600 shares in the last quarter. Finally, Swiss National Bank bought a new stake in shares of Eidos Therapeutics in the 2nd quarter valued at $426,000. 30.46% of the stock is currently owned by institutional investors.
In other news, insider Jonathan C. Fox sold 15,000 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $55.25, for a total value of $828,750.00. Also, CFO Christine Siu sold 20,000 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $59.75, for a total value of $1,195,000.00. In the last three months, insiders sold 112,500 shares of company stock worth $6,273,275. 70.10% of the stock is currently owned by company insiders.
Eidos Therapeutics Company Profile
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Featured Article: How Buying a Call Option Works
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.